New study links immune-related thyroid issues to improved outcomes in patients with advanced non-small cell lung cancer. Non-Small Cell Lung Cancer: An Ongoing Challenge Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung […]
The most prevalent type of lung cancer is non-small cell lung cancer (NSCLC). The clinical application of targeted medicines has accelerated the advancement of NSCLC treatment. Nevertheless, the prognosis of NSCLC patients is still poor […]
Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer, and the epidermal growth factor receptor (EGFR) is the major and well-studied gene that can transform a cell into a tumor cell in […]
V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a novel negative immune checkpoint that has been linked to immunotherapy resistance and might be used as a therapeutic target. It is found overexpressed in non-small cell […]
Lung cancer represents one of the top malignancies in cancer-related incidence and mortality worldwide. Throughout the years, efforts have been made to develop new therapeutic options that can provide an improved quality of life and […]
Copyright (c) 2021 Association of Basic Medical Sciences of FBIH